摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(Z)-3-(3-hydroxy-4-methoxyphenyl)-2-methoxy-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one | 527750-23-8

中文名称
——
中文别名
——
英文名称
(Z)-3-(3-hydroxy-4-methoxyphenyl)-2-methoxy-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
英文别名
(Z)-3-(3-Hydroxy-4-methoxy-phenyl)-2-methoxy-1-(3,4,5-trimethoxy-phenyl)-propenone
(Z)-3-(3-hydroxy-4-methoxyphenyl)-2-methoxy-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one化学式
CAS
527750-23-8
化学式
C20H22O7
mdl
——
分子量
374.39
InChiKey
FNILUMSXQRNRNV-SXGWCWSVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    120-122 °C
  • 沸点:
    573.3±50.0 °C(Predicted)
  • 密度:
    1.219±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.4
  • 重原子数:
    27
  • 可旋转键数:
    8
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    83.4
  • 氢给体数:
    1
  • 氢受体数:
    7

SDS

SDS:05f68768bd3f78cf283dcf0c64137aad
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    异香兰素2-methoxy-1-(3,4,5-trimethoxyphenyl)-1-ethanone哌啶溶剂黄146 作用下, 以 乙醇 为溶剂, 反应 48.0h, 以31%的产率得到(Z)-3-(3-hydroxy-4-methoxyphenyl)-2-methoxy-1-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
    参考文献:
    名称:
    Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: Synthesis and biological evaluation of antivascular activity
    摘要:
    The alpha-methyl chalcone SD400 is a potent inhibitor of tubulin assembly and possesses potent anticancer activity. Various chalcone analogues were synthesized and evaluated for their cell growth inhibitory properties against the K562 human chronic myelogenous leukemia cell line (SD400, IC50 0.21 nM; combretastatin A4 CA4, IC50 2.0 nM). Cell cycle analysis by flow cytometry indicated that these agents are antimitotic (SD400, 83% of the cells are in G(2)/M phase; CA4 90%). They inhibit tubulin assembly at low concentration (SD400, IC50 0.46 mu M; CA4, 0.10 mu M) and compete with [H-3] colchicine for binding to tubulin (8% [H-3] colchicine remained bound to tubulin after competition with SD400 or CA4). Upon treatment with SD400, remarkable cell shape changes were elicited in HUVEC cells, consistent with vasculature damaging activity. (C) 2009 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2009.09.039
点击查看最新优质反应信息

文献信息

  • Combretastatin a-4 derivatives having antineoplastic activity
    申请人:Lawrence James Nicholas
    公开号:US20050065213A1
    公开(公告)日:2005-03-24
    Compounds are disclosed that are designed to mimic the activity of combretastatin A-4 based on chalcone, aurone, or indanone structures, or involving benzoquinone or quinone rings. The anti-cancer activity of exemplified compounds is demonstrated in a range of in vitro and in vivo assays.
    公开了一些化合物,这些化合物是基于查尔酮、金合欢素或茚酮结构设计的,或涉及苯醌或醌环,旨在模仿紫杉醇A-4的活性。在一系列体外和体内试验中,展示了这些化合物的抗癌活性。
  • Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: Synthesis and biological evaluation of antivascular activity
    作者:Sylvie Ducki、David Rennison、Meiko Woo、Alexander Kendall、Jérémie Fournier Dit Chabert、Alan T. McGown、Nicholas J. Lawrence
    DOI:10.1016/j.bmc.2009.09.039
    日期:2009.11
    The alpha-methyl chalcone SD400 is a potent inhibitor of tubulin assembly and possesses potent anticancer activity. Various chalcone analogues were synthesized and evaluated for their cell growth inhibitory properties against the K562 human chronic myelogenous leukemia cell line (SD400, IC50 0.21 nM; combretastatin A4 CA4, IC50 2.0 nM). Cell cycle analysis by flow cytometry indicated that these agents are antimitotic (SD400, 83% of the cells are in G(2)/M phase; CA4 90%). They inhibit tubulin assembly at low concentration (SD400, IC50 0.46 mu M; CA4, 0.10 mu M) and compete with [H-3] colchicine for binding to tubulin (8% [H-3] colchicine remained bound to tubulin after competition with SD400 or CA4). Upon treatment with SD400, remarkable cell shape changes were elicited in HUVEC cells, consistent with vasculature damaging activity. (C) 2009 Elsevier Ltd. All rights reserved.
查看更多